Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 2, 2011, Pages 567-574

  Wallis, Robert S ^a   Jakubiec, Wesley ^b   Kumar, Vikas ^a   Bedarida, Gabriella ^a   Silvia, Annette ^a   Paige, Darcy ^a   Zhu, Tong ^a   Mitton Fry, Mark ^a   Ladutko, Lynn ^b   Campbell, Sheldon ^b,c   Miller, Paul F ^a  

^a PFIZER INC   (United States)

^b VA CT Healthcare   (United States)

^c YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CIPROFLOXACIN; LINEZOLID; METRONIDAZOLE; MITOCHONDRIAL PROTEIN; OXAZOLIDINONE DERIVATIVE; PLACEBO; PNU 100480; PNU 101244; PNU 101603; PYRAZINAMIDE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BLOOD CULTURE; BLOOD TOXICITY; COHORT ANALYSIS; COLITIS; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MONITORING; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; EUPHORIA; EX VIVO STUDY; FATIGUE; FLANK PAIN; GASTROINTESTINAL SYMPTOM; GROWTH INHIBITION; HEMATOCHEZIA; HUMAN; HUMAN EXPERIMENT; IC 50; INTERTRIGO; LEUKOCYTE COUNT; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NAUSEA; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; RHINITIS; SIDE EFFECT; SOMNOLENCE; THORAX PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION; TUBERCULOSIS; URINARY FREQUENCY;

EID: 78751693374     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01179-10     Document Type: Article

References (32)

1. Alcala, L., M. J. Ruiz-Serrano, T. C. Perez-Fernandez, D. Garcia de Viedma, M. Diaz-Infantes, M. Marin-Arriaza, and E. Bouza. 2003. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs. Antimicrob. Agents Chemother. 47:416-417.
2. Anger, H. A., F. Dworkin, S. Sharma, S. S. Munsiff, D. M. Nilsen, and S. D. Ahuja. 2010. Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-06. J. Antimicrob. Chemother. 65:775-783.
3. Attassi, K., E. Hershberger, R. Alam, and M. J. Zervos. 2002. Thrombocytopenia associated with linezolid therapy. Clin. Infect. Dis. 34:695-698.
4. Barbachyn, M. R., D. K. Hutchinson, S. J. Brickner, M. H. Cynamon, J. O. Kilburn, S. P. Klemens, S. E. Glickman, K. C. Grega, S. K. Hendges, D. S. Toops, C. W. Ford, and G. E. Zurenko. 1996. Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity. J. Med. Chem. 39:680-685.
5. Condos, R., N. Hadgiangelis, E. Leibert, G. Jacquette, T. Harkin, and W. N. Rom. 2008. Case series report of a linezolid-containing regimen for extensively drug-resistant tuberculosis. Chest 134:187-192.
6. Cynamon, M. H., S. P. Klemens, C. A. Sharpe, and S. Chase. 1999. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrob. Agents Chemother. 43:1189-1191.
7. Fortun, J., P. Martin-Davila, E. Navas, M. J. Perez-Elias, J. Cobo, M. Tato, E. G. de la Pedrosa, E. Gomez-Mampaso, and S. Moreno. 2005. Linezolid for the treatment of multidrug-resistant tuberculosis. J. Antimicrob. Chemother. 56:180-185.
8. Hugonnet, J. E., L. W. Tremblay, H. I. Boshoff, C. E. Barry III, and J. S. Blanchard. 2009. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science 323:1215-1218.
9. Hui, M., C. Au-Yeang, K. T. Wong, C. Y. Chan, W. W. Yew, and C. C. Leung. 2008. Post-antibiotic effects of linezolid and other agents against Mycobacterium tuberculosis. Int. J. Antimicrob. Agents 31:395-396.
10. Janulionis, E., C. Sofer, S. Schwander, D. Simmons, B. Kreiswirth, E. Shashkina, and R. S. Wallis. 2005. Survival and replication of clinical Mycobacterium tuberculosis isolates in the context of human innate immunity. Infect. Immun. 73:2595-2601.
11. Janulionis, E., C. Sofer, H. Y. Song, and R. S. Wallis. 2004. Lack of activity of oral clofazimine against intracellular Mycobacterium tuberculosis in whole-blood culture. Antimicrob. Agents Chemother. 48:3133-3135.
12. Jindani, A., C. J. Dore, and D. A. Mitchison. 2003. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am. J. Respir. Crit. Care Med. 167:1348-1354.
13. Koh, W. J., O. J. Kwon, H. Gwak, J. W. Chung, S. N. Cho, W. S. Kim, and T. S. Shim. 2009. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J. Antimicrob. Chemother. 64:388-391.
14. Louie, A., C. Fregeau, W. Liu, H. Conde, R. Kulawy, and G. L. Drusano. 2009. Defining the impact of granulocytes on the kill of methicillin-resistant Staphylococcus aureus by the new oxazolidinone prodrug TR-701, abstr. A1-1935. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
15. McKee, E. E., M. Ferguson, A. T. Bentley, and T. A. Marks. 2006. Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrob. Agents Chemother. 50:2042-2049.
16. Migliori, G. B., B. Eker, M. D. Richardson, G. Sotgiu, J. P. Zellweger, A. Skrahina, J. Ortmann, E. Girardi, H. Hoffmann, G. Besozzi, N. Bevilacqua, D. Kirsten, R. Centis, and C. Lange. 2009. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur. Respir. J. 34:387-393.
17. Nagiec, E. E., L. Wu, S. M. Swaney, J. G. Chosay, D. E. Ross, J. K. Brieland, and K. L. Leach. 2005. Oxazolidinones inhibit cellular proliferation via inhibition of mitochondrial protein synthesis. Antimicrob. Agents Chemother. 49:3896-3902.
18. Nam, H. S., W. J. Koh, O. J. Kwon, S. N. Cho, and T. S. Shim. 2009. Daily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis. Int. J. Antimicrob. Agents 33:92-93.
19. Park, I. N., S. B. Hong, Y. M. Oh, M. N. Kim, C. M. Lim, S. D. Lee, Y. Koh, W. S. Kim, D. S. Kim, W. D. Kim, and T. S. Shim. 2006. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrugresistant tuberculosis. J. Antimicrob. Chemother. 58:701-704.
20. Pfizer. 2010. Zyvox package insert. Pfizer Inc., New York. http://media.pfizer.com/files/products/uspi-zyvox.pdf. Last accessed 12 July 2010.
21. Udwadia, Z. F., T. Sen, and G. Moharil. 2010. Assessment of linezolid efficacy and safety in MDR- and XDR-TB: an Indian perspective. Eur. Respir. J. 35:936-938.
22. von der Lippe, B., P. Sandven, and O. Brubakk. 2006. Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB)-a report of ten cases. J. Infect. 52:92-96. (Pubitemid 43137390)
23. Wallis, R. S., W. Jakubiec, V. Kumar, A. M. Silvia, D. Paige, D. Dimitrova, X. Li, L. Ladutko, S. Campbell, G. Friedland, M. Mitton-Fry, and P. F. Miller. 2010. Pharmacokinetics and whole blood bactericidal activity against Mycobacterium tuberculosis of single ascending doses of PNU-100480 in healthy volunteers. J. Infect. Dis. 202:745-751.
24. Wallis, R. S., M. Pai, D. Menzies, T. M. Doherty, G. Walzl, M. D. Perkins, and A. Zumla. 2010. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet 375:1920-1937.
25. Wallis, R. S., M. Palaci, S. Vinhas, A. G. Hise, F. C. Ribeiro, K. Landen, S. H. Cheon, H. Y. Song, M. Phillips, R. Dietze, and J. J. Ellner. 2001. A whole blood bactericidal assay for tuberculosis. J. Infect. Dis. 183:1300-1303.
26. Wallis, R. S., S. Vinhas, and E. Janulionis. 2009. Strain specificity of antimycobacterial immunity in whole blood culture after cure of tuberculosis. Tuberculosis (Edinb.) 9:221-224.
27. Wallis, R. S., S. A. Vinhas, J. L. Johnson, F. C. Ribeiro, M. Palaci, R. L. Peres, R. T. Sa, R. Dietze, A. Chiunda, K. Eisenach, and J. J. Ellner. 2003. Whole blood bactericidal activity during treatment of pulmonary tuberculosis. J. Infect. Dis. 187:270-278.
28. Williams, K. N., S. J. Brickner, C. K. Stover, T. Zhu, A. Ogden, R. Tasneen, S. Tyagi, J. H. Grosset, and E. L. Nuermberger. 2009. Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis. Am. J. Respir. Crit. Care Med. 180:371-376.
29. Williams, K. N., C. K. Stover, T. Zhu, R. Tasneen, S. Tyagi, J. H. Grosset, and E. Nuermberger. 2008. Promising anti-tuberculosis activity of the oxazolidinone PNU-100480 relative to linezolid in the murine model. Antimicrob. Agents Chemother. 53:1314-1319.
30. World Health Organization. 2010. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. WHO/HTM/TB/2010.3. World Health Organization, Geneva, Switzerland. http://whqlibdoc.who.int/publications/2010/9789241599191-eng.pdf. Last accessed 12 July 2010.
31. Yew, W. W., C. H. Chau, and K. H. Wen. 2008. Linezolid in the treatment of 'difficult' multidrug-resistant tuberculosis. Int. J. Tuber. Lung Dis. 12:345-346.
32. Zhang, Y., and D. Mitchison. 2003. The curious characteristics of pyrazinamide: a review. Int. J. Tuber. Lung Dis. 7:6-21.